GDF-15 levels to predict early outcomes after LVAD implantation
Association of Preoperative GDF-15 Levels With Early Postoperative Outcomes and Mortality After LVAD Implantation
Akdeniz University · NCT07497308
We will see if pre-surgery blood levels of GDF-15 can predict early complications or death in adults having an LVAD implanted.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 48 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Akdeniz University (other) |
| Locations | 1 site (Antalya, Please Select:) |
| Trial ID | NCT07497308 on ClinicalTrials.gov |
What this trial studies
This observational study will enroll adults with advanced heart failure who are scheduled to receive a left ventricular assist device at Akdeniz University. Preoperative serum GDF-15 will be measured and patients will be followed through the early postoperative period to record complications, mortality, and other short-term clinical outcomes. Statistical analyses will examine whether higher preoperative GDF-15 is associated with greater risk of early adverse events after LVAD surgery. The goal is to determine whether GDF-15 could improve preoperative risk stratification and inform perioperative management.
Who should consider this trial
Good fit: Adults aged 18 or older with advanced heart failure who are scheduled for LVAD implantation and can provide a preoperative blood sample and informed consent.
Not a fit: Patients under 18, those with active infection, active malignancy, severe hepatic failure, or missing required data are unlikely to benefit from GDF-15–based risk information in this project.
Why it matters
Potential benefit: If successful, preoperative GDF-15 measurement could help identify patients at higher risk for early complications or death and guide perioperative planning to improve outcomes.
How similar studies have performed: Previous research in heart failure and cardiac surgery populations has suggested GDF-15 has prognostic value, but its specific use for predicting early LVAD outcomes remains relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:Adults aged 18 years and older Patients with advanced heart failure undergoing LVAD implantation Availability of preoperative GDF-15 measurement Ability to provide written informed consent or consent provided by a legally authorized representative, according to local regulations - Exclusion Criteria:Age under 18 years Active infection Active malignancy Severe hepatic failure Missing study data Refusal to participate \-
Where this trial is running
Antalya, Please Select:
- Akdeniz University, Faculty of Medicine, Department of Anesthesiology and Reanimation — Antalya, Please Select:, Turkey (Türkiye) (RECRUITING)
Study contacts
- Study coordinator: emel gündüz, md
- Email: dregunduz@hotmail.com
- Phone: +902422496000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Advanced Heart Failure, Left Ventricular Assist Device Implantation, Left Ventricular Assist Device, GDF-15, Postoperative Outcomes, Early Mortality